No, Imdur is NOT a short-acting nitrate
Imdur (isosorbide mononitrate) is a long-acting, sustained-release nitrate formulation designed for once-daily dosing, providing antianginal effects for up to 12 hours. 1
Classification and Mechanism
The 2024 ESC Guidelines clearly distinguish between short-acting nitrates (recommended for immediate relief of angina) and long-acting nitrates (recommended as add-on therapy or part of initial treatment for symptom control) 1. Imdur falls squarely into the long-acting category.
Pharmacokinetic Profile
Imdur uses the Durules principle—an insoluble matrix embedding system that achieves controlled medication release 2. This formulation:
- Provides effective antianginal prophylaxis for approximately 1 to 12 hours after administration 2
- Maintains therapeutic plasma concentrations throughout the day when dosed once daily in the morning 2, 3
- Creates a plasma nitrate profile high enough for daytime protection but low enough during the latter dosage interval to potentially avoid tolerance development 3
Clinical Evidence
Studies demonstrate that Imdur 60 mg once daily (the most widely studied dose) maintains antianginal efficacy comparable to:
The sustained-release formulation significantly improves exercise capacity and reduces anginal attacks when added to beta-blocker therapy, with effects persisting during long-term treatment 4.
Important Caveats
- Tolerance concerns: While some studies show maintained efficacy during repeated administration 2, 4, one study found loss of statistical superiority over placebo at 6 weeks with doses ≤60 mg/day 2
- Abrupt withdrawal: Discontinuation after long-term treatment may exacerbate anginal symptoms 5
- Headache is the most common adverse effect but typically improves with continued therapy 2
In contrast to short-acting nitrates (like sublingual nitroglycerin) used for acute symptom relief, Imdur is intended for chronic prophylaxis of angina symptoms, not immediate relief.